CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+18.02%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$1.06B
AUM Growth
-$12.1M
(-1.1%)
Cap. Flow
-$153M
Cap. Flow
% of AUM
-14.42%
Top 10 Holdings %
Top 10 Hldgs %
37.54%
Holding
501
New
15
Increased
262
Reduced
172
Closed
24
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$6.59M |
| 2 |
iShares Gold Trust Micro
IAUM
|
$4.62M |
| 3 |
Intuit
INTU
|
$3.73M |
| 4 |
SPDR Gold MiniShares Trust
GLDM
|
$3.6M |
| 5 |
T-Mobile US
TMUS
|
$2.35M |
Top Sells
| 1 |
Apple
AAPL
|
$17.4M |
| 2 |
NVIDIA
NVDA
|
$12.2M |
| 3 |
Microsoft
MSFT
|
$11.5M |
| 4 |
Amazon
AMZN
|
$8.86M |
| 5 |
Broadcom
AVGO
|
$8.43M |
Sector Composition
| 1 | Technology | 38.15% |
| 2 | Healthcare | 22.68% |
| 3 | Communication Services | 12.64% |
| 4 | Consumer Discretionary | 11.62% |
| 5 | Consumer Staples | 3.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
CorMedix
CRMD
$966M
| $168K | 0.02% |
13,622
+1,451
| +12% | +$17.9K |
|
|
LENZ
327
LENZ Therapeutics
LENZ
$1.13B
| $166K | 0.02% |
5,653
+137
| +2% | +$4.02K |
|
328
Cogent Biosciences
COGT
$1.81B
| $164K | 0.02% |
22,868
+32
| +0.1% | +$230 |
|
329
Syndax Pharmaceuticals
SNDX
$1.38B
| $162K | 0.02% |
17,282
+161
| +0.9% | +$1.51K |
|
330
Anavex Life Sciences
AVXL
$787M
| $158K | 0.01% |
17,147
+85
| +0.5% | +$784 |
|
331
Zoetis
ZTS
$67.6B
| $154K | 0.01% |
986
| – | – |
|
332
uniQure
QURE
$946M
| $153K | 0.01% |
10,996
-578
| -5% | -$8.06K |
|
333
Zeekr
ZK
$7.3B
| $153K | 0.01% |
6,000
-6,000
| -50% | -$153K |
|
334
Xeris Biopharma Holdings
XERS
$1.27B
| $150K | 0.01% |
32,167
+2,264
| +8% | +$10.6K |
|
335
ArriVent BioPharma
AVBP
$782M
| $150K | 0.01% |
6,871
+112
| +2% | +$2.44K |
|
336
Monte Rosa Therapeutics
GLUE
$303M
| $146K | 0.01% |
32,354
+20,031
| +163% | +$90.3K |
|
337
Oric Pharmaceuticals
ORIC
$1.03B
| $145K | 0.01% |
14,278
+31
| +0.2% | +$315 |
|
338
Replimune Group
REPL
$452M
| $144K | 0.01% |
15,483
+35
| +0.2% | +$325 |
|
339
Vir Biotechnology
VIR
$717M
| $140K | 0.01% |
27,765
+256
| +0.9% | +$1.29K |
|
340
Phathom Pharmaceuticals
PHAT
$821M
| $134K | 0.01% |
14,022
+307
| +2% | +$2.94K |
|
341
Day One Biopharmaceuticals
DAWN
$757M
| $132K | 0.01% |
20,358
+28
| +0.1% | +$182 |
|
342
AnaptysBio
ANAB
$589M
| $131K | 0.01% |
5,901
-250
| -4% | -$5.55K |
|
343
EyePoint Pharmaceuticals
EYPT
$802M
| $130K | 0.01% |
13,821
+131
| +1% | +$1.23K |
|
344
UroGen Pharma
URGN
$860M
| $127K | 0.01% |
9,261
+797
| +9% | +$10.9K |
|
345
Stoke Therapeutics
STOK
$1.06B
| $124K | 0.01% |
10,966
+342
| +3% | +$3.88K |
|
346
Sana Biotechnology
SANA
$736M
| $124K | 0.01% |
45,302
+518
| +1% | +$1.41K |
|
347
Taysha Gene Therapies
TSHA
$881M
| $121K | 0.01% |
52,527
+11,407
| +28% | +$26.4K |
|
348
Evolus
EOLS
$479M
| $119K | 0.01% |
12,950
+249
| +2% | +$2.29K |
|
349
Relay Therapeutics
RLAY
$695M
| $119K | 0.01% |
34,434
+431
| +1% | +$1.49K |
|
350
Arbutus Biopharma
ABUS
$769M
| $119K | 0.01% |
38,467
+458
| +1% | +$1.42K |
|